Component

LathMized NAD+ formulation

Context-specific entity; species, compartment and exposure are stated on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. A five-day placebo-controlled trial of oral LNAD+ reported whole-blood intracellular NAD 53% higher versus placebo at day six; 60 adults were randomized and 50 entered the primary analysis.

    LathMized NAD+ formulation → Whole-blood intracellular NAD measurement source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Healthy adults aged 45–75; short phase 0/1b trial, NCT07336836, retrospectively registered.
    limitations
    Primary abstract only. Formulation-specific, no isotope-traced intact uptake, no inference about muscle or brain NAD; exclusions and assay details require full-report appraisal.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    A particular oral formulation increased a blood-cell-associated NAD measure.
    primary_references
    Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 308–314

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Healthy adults aged 45–75; short phase 0/1b trial, NCT07336836, retrospectively registered. · source_derived_draft · unverified_draft

    ## nad-plus-oral-formulation-blood A particular oral formulation increased a blood-cell-associated NAD measure. A five-day placebo-controlled trial of oral LNAD+ reported whole-blood intracellular NAD 53% higher versus placebo at day six; 60 adults were randomized and 50 entered the primary analysis. Model: Healthy adults aged 45–75; short phase 0/1b trial, NCT07336836, retrospectively registered. Limitations: Primary abstract only. Formulation-specific, no isotope-traced intact uptake, no inference about muscle or brain NAD; exclusions and assay details require full-report appraisal. Evidence access: Primary abstract Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    Complete structured claim and evidence

  2. No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm.

    LathMized NAD+ formulation → Short-term clinical endpoints in the LNAD trial source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Same short trial; exploratory secondary outcomes.
    limitations
    Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    A large biomarker change did not establish a clinical benefit.
    primary_references
    Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 324–330

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same short trial; exploratory secondary outcomes. · source_derived_draft · unverified_draft

    ## nad-plus-oral-formulation-clinical-null A large biomarker change did not establish a clinical benefit. No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm. Model: Same short trial; exploratory secondary outcomes. Limitations: Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record. Evidence access: Primary abstract Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    Complete structured claim and evidence

  3. The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased.

    LathMized NAD+ formulation → Human plasma NAD concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Same five-day randomized trial; primary analysis n=50.
    limitations
    Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Blood compartments and breakdown products can move differently.
    primary_references
    Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 316–322

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same five-day randomized trial; primary analysis n=50. · source_derived_draft · unverified_draft

    ## nad-plus-oral-formulation-plasma Blood compartments and breakdown products can move differently. The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased. Model: Same five-day randomized trial; primary analysis n=50. Limitations: Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake. Evidence access: Primary abstract Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards